Ruxolitinib is a drug which blocks the Janus tyrosine Kinase (JAK) signaling pathway. It is
thought that this pathway might be important in certain types of breast cancer, and that
blocking this pathway might lead to anti-cancer effects. This study is testing the effects of
ruxolitinib in patients with breast cancer.